CD8A and neoplasm: Preclinical studies have verified the promising effects of eliminating FAP-positive CAFs to increase the recruitments of anti-tumor CD8 + T cells into tumor stroma, hence rekindling the anti-tumor immunity and suppressing tumor progression [29, 30].